TME Pharma receives US FDA Fast Track designation for lead asset NOX-A12 in brain cancer
Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in…
Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in…
Clinical trial protocol approved in the US to initiate Phase 2 study with NOX-A12 in glioblastoma providing a clear road…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
€1.48 million private placement secured from a group of new investors Buyback will mark the end of TME Pharma's converti…
Constructive meeting held with FDA provided feedback and clear guidance on key aspects of further development of NOX…
. Median overall survival surpasses 19 months and continues to improve in glioblastoma patients receiving NOX-A12 comb…
L'opération a permis de lever un montant total de 2,7 millions d'euros et d'émettre 10,8 millions d'actions nouvelles. L…
Transaction raised the full amount of €2.7 million leading to the issuance of 10.8 million new shares Strong demand prim…
Ces informations ne sont pas destinées aux résidents du Royaume-Uni, des États-Unis, de l'Australie, du Canada ou du Jap…
This information is not intended for residents of the United Kingdom, United States, Australia, Canada or Japan. See Ann…